The $2.2 billion heavyweight variety will be taken down first.

Pharmaceutical Network August 13th, August 7th, the first sound pharmaceutical industry according to the imitation of 4 categories of reportedacid tofatic cloth tablets (acceptance number CYHS1900544) for the status of change to "in approval", is expected to be approved in recent days and treated as a review.
the third batch of collections, Xeljanz reported global sales of $2,242 million in 2019, up 26% year-on-year, according to Pfizer.
is the world's first approved small molecule for the treatment of rheumatoid arthritis targeting JAK kinase inhibitors.
Tofatib, developed by Pfizer and named Xeljanz ,was approved by the FDA on November 6, 2012 for the treatment of adult patients with moderate to severe rheumatoid arthritis who are underreacted or insensitive to methotrexate.
Pfizer's global sales in millions of dollars, Xeljanz reported global sales of $2,242 million in 2019, up 26% year-on-year.
2017, Xeljanz was approved for import by the State Drug Administration, and the domestic market is still in the pioneering stage.
acid tofatic cloth pieces for the third batch of harvest varieties.
At present, there are 5 pharmaceutical companies in China
the third batch of collection will be opened on August 20, Colum Pharmaceuticals, Yangzijiang Pharmaceutical Group, Nanjing Zhengtianqing have rushed to the collection before the approval of the listing.
acid tofatide cloth tablets evaluation enterprise minenet data show that Stone Pharmaceutical Group, Vit Pharmaceuticals, Haizheng Pharmaceuticals and other 9 enterprises of theacid tofatic cloth tablets listing application is under review.
the registration status of the Sonic Pharmaceuticals" acid tote cloth tablets has been changed to "in the approval", if successfully approved will be regarded as an over-evaluation, to win the collection of entry vouchers.
theof the phosphonate tote cloth film listing application in the review enterprise source: Mi Net database, NMPA.